Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Randomized Double-blind Phase III Clinical Trial Comparing Safety and Efficacy of BCD-022 (CJSC BIOCAD, Russia) Used With Paclitaxel to Herceptin® Used With Paclitaxel in the First-line Treatment of HER2+ Metastatic Breast Cancer Patients

NCT01764022 is registered in ClinicalTrials.gov with Biocad as lead sponsor.

NCT NCT01764022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01764022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Randomized Double-blind Phase III Clinical Trial Comparing Safety and Efficacy of BCD-022 (CJSC BIOCAD, Russia) Used With Paclitaxel to Herceptin® Used With Paclitaxel in the First-line Treatment of HER2+ Metastatic Breast Cancer Patients
Lead sponsor
Biocad
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2012
Completion date
December 31, 2017
Enrollment
225 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

human epithelial receptor (her)-2 positive breast cancer